26 May 2013
Keywords: ImmuNext, Janssen Biotech, Johnson & Johnson, Cancer drug discovery
Article | 06 September 2012
Closely-held USA-based ImmuNext has entered into an agreement with Janssen Biotech, a unit of US health care giant Johnson & ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
6 September 2012
24 May 2013
© 2013 thepharmaletter.com